Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | TDO2 | P48775 | 1/20 | 0.49 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.45 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725960 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL2825852 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL6406357 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL2825850 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL13207340 | 0.86 | TDP1 (0.75) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL6744832 | 0.85 | TDP1 (0.73) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL6744829 | 0.85 | TDP1 (0.73) | TDP1MAPTALDH1A1GAATTR | |
| SCHEMBL7014287 | 0.83 | TDP1 (0.71) | TDP1MAPTALDH1A1LRRK2IDO1 | |
| SCHEMBL7006381 | 0.82 | TDP1 (0.69) | TDP1MAPTALDH1A1LRRK2IDO1 | |
| SCHEMBL5468788 | 0.81 | TDP1 (0.68) | TDP1MAPTALDH1A1LRRK2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250205467-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER USING ULTRASOUND | DUKE UNIVERSITY | 2025-06-26 | — | — | US | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20250066853-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF ANEURYSMS, DIAGNOSTIC SUPPORT METHOD FOR ANEURYSMS, AND METHOD FOR EVALUATING ANEURYSM THERAPEUTICS | RIKEN (JP) | 2025-02-27 | — | — | US | disclosed |
| EP-4498942-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER USING ULTRASOUND | Duke University (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119136746-A | System and method for treating cancer using ultrasound | 杜克大学 | 2024-12-13 | — | — | CN | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| EP-4458375-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING ARTERIAL ANEURYSM, METHOD FOR ASSISTING DIAGNOSIS OF ARTERIAL ANEURYSM, AND METHOD FOR ASSESSING THERAPEUTIC DRUG FOR ARTERIAL ANEURYSM | Nakatomi, Hirofumi (JP) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023243971-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEMYELINATING DISEASE, COMPRISING KINASE INHIBITOR AS ACTIVE INGREDIENT | 고려대학교 산학협력단 | 2023-12-21 | — | — | WO | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| WO-2023192329-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER USING ULTRASOUND | DUKE UNIVERSITY (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023127909-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING ARTERIAL ANEURYSM, METHOD FOR ASSISTING DIAGNOSIS OF ARTERIAL ANEURYSM, AND METHOD FOR ASSESSING THERAPEUTIC DRUG FOR ARTERIAL ANEURYSM | 国立研究開発法人理化学研究所 | 2023-07-06 | — | — | WO | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-11364043-B2 | Methods and devices for endovascular therapy | CARDIOPROLIFIC INC. (US) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066853-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF ANEURYSMS, DIAGNOSTIC SUPPORT METHOD FOR ANEURYSMS, AND METHOD FOR EVALUATING ANEURYSM THERAPEUTICS | PDGFRB, PDGFRA, PDGFA | TDP1 1904/4885MAPT 3199/4885ALDH1A1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.